Novo Nordisk to test diabetes tablet against Eli Lilly drug

A clinical trial will compare the effect of Novo Nordisk’s semaglutide with Eli Lilly’s Jardiance on patients’ blood sugar levels and body weight.

Photo: Novo Nordisk / PR

In a new clinical study, Novo Nordisk is seeking to measure the efficacy and safety of a once-daily tablet version of semaglutide, comparing the drug to Eli Lilly’s daily tablet treatment, empagliflozin, according to a filing on database Clinical Trials.

In a patient population aged 18–50 with newly diagnosed type 2 diabetes and obesity, the study aims to see ”how well the blood sugar and body weight are controlled” for patients on either of the two drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs